La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

DexCom Gestione

Gestione criteri di controllo 3/4

DexCom's Il CEO è Kevin Sayer, nominato in Jun2011, e ha un mandato di 13.17 anni. la retribuzione annua totale è $ 15.71M, composta da 7% di stipendio e 93% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.043% delle azioni della società, per un valore di € 11.38M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 2.6 anni e 8.6 anni.

Informazioni chiave

Kevin Sayer

Amministratore delegato

US$15.7m

Compenso totale

Percentuale dello stipendio del CEO	7.0%
Mandato del CEO	13.3yrs
Proprietà del CEO	0.04%
Durata media del management	2.7yrs
Durata media del Consiglio di amministrazione	8.7yrs

Aggiornamenti recenti sulla gestione

Recent updates

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Kevin Sayer rispetto agli utili di DexCom?
Data	Compenso totale	Stipendio	Guadagni aziendali
Jun 30 2024	n/a	n/a	US$667m
Mar 31 2024	n/a	n/a	US$639m
Dec 31 2023	US$16m	US$1m	US$542m
Sep 30 2023	n/a	n/a	US$377m
Jun 30 2023	n/a	n/a	US$358m
Mar 31 2023	n/a	n/a	US$293m
Dec 31 2022	US$15m	US$953k	US$341m
Sep 30 2022	n/a	n/a	US$244m
Jun 30 2022	n/a	n/a	US$230m
Mar 31 2022	n/a	n/a	US$258m
Dec 31 2021	US$12m	US$900k	US$217m
Sep 30 2021	n/a	n/a	US$577m
Jun 30 2021	n/a	n/a	US$562m
Mar 31 2021	n/a	n/a	US$530m
Dec 31 2020	US$14m	US$800k	US$550m
Sep 30 2020	n/a	n/a	US$231m
Jun 30 2020	n/a	n/a	US$205m
Mar 31 2020	n/a	n/a	US$148m
Dec 31 2019	US$10m	US$691k	US$101m
Sep 30 2019	n/a	n/a	-US$171m
Jun 30 2019	n/a	n/a	-US$170m
Mar 31 2019	n/a	n/a	-US$130m
Dec 31 2018	US$10m	US$601k	-US$127m
Sep 30 2018	n/a	n/a	US$43m
Jun 30 2018	n/a	n/a	-US$5m
Mar 31 2018	n/a	n/a	-US$33m
Dec 31 2017	US$8m	US$546k	-US$50m

Compensazione vs Mercato: La retribuzione totale di Kevin ($USD 15.71M ) è superiore alla media delle aziende di dimensioni simili nel mercato Austrian ($USD 4.49M ).

Compensazione vs guadagni: La retribuzione di Kevin è stata coerente con le performance aziendali dell'ultimo anno.

AMMINISTRATORE DELEGATO

Kevin Sayer (66 yo)

13.3yrs

Mandato

US$15,712,244

Compensazione

Mr. Kevin Ronald Sayer has been Executive Chairman of DexCom, Inc. since July 30, 2018. Mr. Sayer has been the Chief Executive Officer of DexCom, Inc. since January 5, 2015 and as its President since June...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Kevin Sayer	Executive Chairman	13.3yrs	US$15.71m	0.043% $ 10.5m
Jereme Sylvain	Executive VP	4.5yrs	US$4.25m	0.0088% $ 2.1m
Jacob Leach	Executive VP & COO	2.1yrs	US$4.94m	0.065% $ 15.7m
Michael Brown	Executive VP & Chief Legal Officer	2.7yrs	US$4.34m	0.0013% $ 322.3k
Teri Lawver	Executive VP & Chief Commercial Officer	1.7yrs	US$6.53m	0.0016% $ 397.5k
Girish Naganathan	Executive VP & CTO	1.9yrs	US$4.05m	0.0013% $ 324.8k
Stacey Stewart	Senior VP & Chief Information Officer	less than a year	Nessun dato	Nessun dato
Sean Christensen	Director of Corporate Affairs & Head of Investor Relations	no data	Nessun dato	Nessun dato
Matthew Dolan	Executive Vice President of Strategy	3.5yrs	Nessun dato	0% $ 0
Leverne Marsh	Executive Vice President of Marketing	less than a year	Nessun dato	Nessun dato
Sadie Stern	Executive VP & Chief Human Resources Officer	4yrs	Nessun dato	0.0058% $ 1.4m
Steven Pacelli	Executive VP & MD of Dexcom Ventures	3.4yrs	US$3.02m	0.021% $ 5.2m

2.7yrs

Durata media

49yo

Età media

Gestione esperta: Il team dirigenziale di DXCM è considerato esperto (durata media dell'incarico 2.6 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Kevin Sayer	Executive Chairman	16.8yrs	US$15.71m	0.043% $ 10.5m
Mark Foletta	Lead Independent Director	9.8yrs	US$393.51k	0.014% $ 3.4m
Steven Altman	Independent Director	10.8yrs	US$343.40k	0.014% $ 3.4m
Eric Topol	Independent Director	15.2yrs	US$346.49k	0.094% $ 22.9m
Nicholas Augustinos	Independent Director	14.8yrs	US$362.21k	0.0092% $ 2.2m
Bridgette Heller	Independent Director	5yrs	US$346.49k	0.0054% $ 1.3m
Kyle Malady	Independent Director	3.9yrs	US$343.40k	0.0039% $ 940.4k
Karen Dahut	Independent Director	4.1yrs	US$345.90k	0.0038% $ 916.1k
Richard Collins	Independent Director	7.5yrs	US$345.90k	0.0098% $ 2.4m
Rimma Driscoll	Independent Director	1.1yrs	US$404.72k	0% $ 0

8.7yrs

Durata media

63yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di DXCM sono considerati esperti (durata media dell'incarico 8.6 anni).

DexCom Gestione

Gestione criteri di controllo 3/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

DexCom, Inc., Annual General Meeting, May 22, 2024

DexCom, Inc., Annual General Meeting, May 22, 2024

Executive Chairman recently sold €3.7m worth of stock

Executive Chairman recently sold €4.2m worth of stock

Insufficient new directors

DexCom, Inc. Announces Appointment of Rimma Driscoll to Its Board of Directors

Recent updates

DexCom, Inc. to Showcase Transformational Impact of Dexcom CGM Technology at the EASD 2024 Conference Symposium

Stelo by Dexcom, the First Over-The-Counter Glucose Biosensor in the U.S., Is Now Available

Levi & Korsinsky, LLP Files Complaint to Recover Losses Suffered by Purchasers of DexCom, Inc

Investor sentiment deteriorates as stock falls 36%

Now 7.0% undervalued after recent price drop

Second quarter 2024 earnings released: EPS: US$0.36 (vs US$0.30 in 2Q 2023)

DexCom, Inc. Updates Earnings Guidance for the Year 2024

DexCom, Inc. to Report Q2, 2024 Results on Jul 25, 2024

Dexcom Showcases Extensive Clinical Data At ADA 2024 Demonstrating the Benefit of Dexcom CGM Use Among People with Type 2 Diabetes

Dexcom, Inc. Announces the Dexcom G7 Continuous Glucose Monitoring System Now Connects Directly to Apple Watch in the United States

Dexcom Wins Access to Dexcom One for 100,000 People Living with Type 2 Diabetes

DexCom, Inc. Provides Earnings Guidance for the Year 2024

First quarter 2024 earnings released: EPS: US$0.38 (vs US$0.13 in 1Q 2023)

DexCom, Inc., Annual General Meeting, May 22, 2024

New minor risk - Shareholder dilution

DexCom, Inc., Annual General Meeting, May 22, 2024

DexCom, Inc. to Report Q1, 2024 Results on Apr 25, 2024

Executive Chairman recently sold €3.7m worth of stock

DexCom, Inc. Announces the FDA Clears Stelo by Dexcom – the First Glucose Biosensor

Now 21% undervalued

Full year 2023 earnings released: EPS: US$1.40 (vs US$0.88 in FY 2022)

DexCom, Inc. Reiterates Revenue Guidance for the Fiscal Year 2024

DexCom, Inc. Launches Dexcom One+ Bringing Powerful, New Diabetes Management Technology to More People

Executive Chairman recently sold €4.2m worth of stock

Dexcom, Inc. Announces the Dexcom G7 Continuous Glucose Monitoring System Now Connects with the t:Slim X2™ Insulin Pump by Tandem Diabetes Care in Countries Across Europe and in South Africa

DexCom, Inc. to Report Q4, 2023 Results on Feb 08, 2024

Dexcom, Inc. Provides Revenue Guidance for the Full Year of 2024

Dexcom, Inc. Announces the Dexcom G7 Continuous Glucose Monitoring System Now Connects with the Tandem t:slim X2 Insulin Pump

Insufficient new directors

DexCom, Inc. (NasdaqGS:DXCM) announces an Equity Buyback for $500 million worth of its shares.

Third quarter 2023 earnings released: EPS: US$0.31 (vs US$0.26 in 3Q 2022)

Now 22% undervalued after recent price drop

Dexcom Solidifies Global Leadership in Continuous Glucose Monitoring with New Clinical Data Presented at EASD

DexCom, Inc. to Report Q3, 2023 Results on Oct 26, 2023

DexCom, Inc Announces the Availability of Its Dexcom One Real-Time CGM Sensor Via Reimbursement, in France

DexCom, Inc. Announces Appointment of Rimma Driscoll to Its Board of Directors

DexCom, Inc. Increases Earnings Guidance for the Fiscal Year 2023

Second quarter 2023 earnings released: EPS: US$0.30 (vs US$0.13 in 2Q 2022)

DexCom, Inc. to Report Q2, 2023 Results on Jul 27, 2023

Dexcom, Inc. Receives Health Canada Approval: Next-Generation Continuous Glucose Monitoring System with Unmatched Accuracy Coming to Canadians

DexCom, Inc. Updates Earnings Guidance for the Year 2025

First quarter 2023 earnings released: EPS: US$0.13 (vs US$0.25 in 1Q 2022)

DexCom, Inc. Reiterates Revenue Guidance for the Fiscal Year 2023

Full year 2022 earnings released: EPS: US$0.88 (vs US$0.40 in FY 2021)

Executive Chairman recently sold €4.5m worth of stock

Dexcom, Inc.'s G6 Real-Time CGM System Now Available to All Clients With Type 1 Diabetes Covered Under the Non-Insured Health Benefits Program

DexCom, Inc. to Report Q4, 2022 Results on Feb 09, 2023

Dexcom, Inc. Receives FDA Clearance of Next-Generation Dexcom G7 Continuous Glucose Monitoring System

Third quarter 2022 earnings released: EPS: US$0.26 (vs US$0.18 in 3Q 2021)

DexCom, Inc. Provides Earnings Guidance for the Year 2022

DexCom, Inc. Announces the Launch of Dexcom U

DexCom, Inc. Announces Launch of Dexcom G7 in the United Kingdom, Ireland, Germany, Austria and Hong Kong – Initiating Global Rollout of World’s Most Powerful Continuous Glucose Monitoring System

DexCom, Inc. to Report Q3, 2022 Results on Oct 27, 2022

DexCom, Inc. Promotes Jacob S. Leach to Chief Operating Officer

DexCom, Inc. Announces One Real-Time Continuous Glucose Monitoring (rt-CGM) System Available on Prescription in the UK

Second quarter 2022 earnings released: EPS: US$0.13 (vs US$0.20 in 2Q 2021)

DexCom, Inc. (NasdaqGS:DXCM) announces an Equity Buyback for $700 million worth of its shares.

DexCom, Inc. Revises Earnings Guidance for the Full Year 2022

DexCom, Inc. Announces Resignation of Chad M. Patterson as Executive Vice President, Global Marketing, Effective July 15, 2022

DexCom, Inc. to Report Q2, 2022 Results on Jul 28, 2022

Dexcom Says Not in Active Merger Talks

Dexcom Reportedly in Talks to Acquire Insulet

First quarter 2022 earnings released: EPS: US$1.00 (vs US$0.42 in 1Q 2021)

DexCom, Inc. Showcases Expanded CGM Portfolio at International ATTD Conference

Now 23% undervalued

Dexcom Announces Dexcom ONE, the Newest Real-Time Continuous Glucose Monitoring System, to Its Range of Scan-Free and Fingerprick†-Free Devices

DexCom, Inc. to Report Q1, 2022 Results on Apr 28, 2022

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

DexCom, Inc. Reiterates Earnings Guidance for the Fiscal Year 2022